GMAB sentiment intelligence

Analysts Are Bullish on Top Healthcare Stocks: Chemomab Therapeutics (CMMB), Genmab (GMAB)

Healthcare sector analysts have issued bullish sentiments on several companies, including Chemomab Therapeutics (CMMB) and Genmab (GMAB). Maxim Group maintained a Buy rating on Chemomab with a $5.00 price target, while William Blair reiterated a Buy rating on Genmab, which has a

Tone

Positive 75/100

Event

Analyst action

Published

15 Jul 2026 16:42

Source

The Globe and Mail

Genmab A/S (Nasdaq: GMAB) reports USD 4,207 million Q2 DARZALEX sales

Genmab A/S reported worldwide net trade sales of its drug DARZALEX (daratumumab), including DARZALEX FASPRO, reached USD 4,207 million in the second quarter of 2026. This total includes USD 2,435 million from U.S. sales and USD 1,772 million from the rest of the world. Genmab rec

Tone

Positive 67/100

Event

Earnings

Published

15 Jul 2026 11:40

Source

Stock Titan

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026

Genmab announced that worldwide net trade sales of DARZALEX (daratumumab) for the second quarter of 2026 totaled USD 4,207 million. This figure includes sales of both intravenous and subcutaneous products, as reported by Johnson & Johnson. Genmab receives royalties on these globa

Tone

Positive 72/100

Event

Earnings

Published

15 Jul 2026 10:40

Source

The Manila Times

Genmab stock reflects biotech growth focus for long-term investors

Genmab stock offers investors a pure-play opportunity in antibody-based cancer and immune therapies, leveraging a royalty-driven revenue model. The Danish biotech's dual Nasdaq listings provide US investors access to its expanding pipeline of differentiated antibody formats and a

Tone

Positive 76/100

Event

Earnings

Published

14 Jul 2026 05:13

Source

Ad Hoc News

Genmab A/S (GMAB) Stock Analysis: Unlocking A 26.68% Upside With Strong Buy Ratings

Tone

Positive 95/100

Event

Market update

Published

13 Jul 2026 09:19

Source

DirectorsTalk Interviews

New data on Novo's hemophilia treatment show few and mild side effects

New long-term data for Novo Nordisk's antihemorrhagic drug mim8, developed in collaboration with Genmab, indicate a reduction in bleeding episodes. The treatment also shows a favorable safety profile with few and mild side effects across all age groups. However, the full article

Tone

Positive 71/100

Event

Market update

Published

13 Jul 2026 08:11

Source

MedWatch

Is Genmab A/S (GMAB) Stock Undervalued After Positive Epkinly DLBCL Trial Results?

H.C. Wainwright analyst Raghuram Selvaraju increased the price target for Genmab A/S (GMAB) to $40 from $38, reaffirming a Buy rating following positive Epkinly DLBCL-4 trial results and increased regulatory approval likelihood. Additionally, the European Commission approved mark

Tone

Positive 75/100

Event

Analyst action

Published

08 Jul 2026 15:10

Source

Market source

Genmab Announces Tepkinly® In Combination With Lenalidomide And Rituximab Is Approved By The European Commission

Genmab announced that the European Commission has approved Tepkinly® in combination with lenalidomide and rituximab. This approval is a significant regulatory milestone for the company and its oncology treatment. The drug regimen is now cleared for use within the European Union.

Tone

Positive 87/100

Event

Regulatory and legal

Published

06 Jul 2026 18:10

Source

TradingView

Genmab A/S

Genmab A/S announced that the European Commission has granted marketing authorization for TEPKINLY (epcoritamab) in combination with lenalidomide and rituximab for the treatment of relapsed or refractory follicular lymphoma (FL). This approval is based on the Phase 3 EPCORE FL-1

Tone

Positive 74/100

Event

Regulatory and legal

Published

06 Jul 2026 18:10

Source

Via Ritzau

BNP Paribas raises the target price for Genmab to 2,500 Danish kroner (2,400), reiterates outperform - BN

BNP Paribas has increased its target price for Genmab to 2,500 Danish kroner, up from 2,400, while maintaining an "outperform" rating. This adjustment reflects a positive outlook on the biotechnology company's future performance. The article also provides recent news on Genmab's

Tone

Positive 71/100

Event

Analyst action

Published

06 Jul 2026 13:10

Source

www.marketscreener.com

H.C. Wainwright raises Genmab stock price target on trial success

H.C. Wainwright has increased its price target for Genmab A/S shares to $40 from $38, maintaining a Buy rating, following successful trial results for the drug EPKINLY. The trial demonstrated a statistically significant improvement in progression-free survival for diffuse large B

Tone

Positive 71/100

Event

Analyst action

Published

02 Jul 2026 14:10

Source

Investing.com

After monotherapy failure, AbbVie and Genmab tout Epkinly combo win in DLBCL

AbbVie and Genmab's Epkinly, despite a recent monotherapy failure, showed a significant win in a Phase 3 combination trial for diffuse large B-cell lymphoma (DLBCL). The drug, combined with lenalidomide, reduced the risk of progression or death by 60% compared to the R-GemOx regi

Tone

Positive 72/100

Event

Market update

Published

30 Jun 2026 13:39

Source

Fierce Pharma

Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival

Genmab announced positive topline results from its Phase 3 EPCORE DLBCL-4 trial, showing that epcoritamab combined with lenalidomide significantly improved progression-free survival in patients with relapsed/refractory diffuse large B-cell lymphoma. The combination reduced the ri

Tone

Positive 73/100

Event

Earnings

Published

30 Jun 2026 12:41

Source

Business Wire

Genmab Shares Climb After Lymphoma Therapy Hits Goal in Trial

Genmab's shares increased in European morning trading after its drug combination with partner AbbVie met the primary goal in a late-stage clinical trial for lymphoma. The stock rose 6%, recovering some year-to-date losses, though it remains down 10% since the start of 2026. AbbVi

Tone

Positive 82/100

Event

Market update

Published

30 Jun 2026 09:39

Source

WSJ

Genmab stock rallies after Epkinly shows strong results in 2L lymphoma trial

Genmab shares surged after its drug Epkinly, combined with lenalidomide, delivered strong interim data in a late-stage trial for second-line diffuse large B-cell lymphoma. The results showed a progression-free survival hazard ratio of 0.40, easing previous investor concerns after

Tone

Positive 75/100

Event

Earnings

Published

30 Jun 2026 08:39

Source

Investing.com

Genmab reports positive phase 3 trial results for lymphoma drug

Genmab A/S announced positive Phase 3 trial results for its lymphoma drug epcoritamab, showing statistically significant improvement in progression-free survival for patients with relapsed or refractory diffuse large B-cell lymphoma. The company reported strong financial momentum

Tone

Positive 74/100

Event

Earnings

Published

30 Jun 2026 00:12

Source

Investing.com